IL324993A - שיטות לטיפול במיאלומה נפוצה - Google Patents

שיטות לטיפול במיאלומה נפוצה

Info

Publication number
IL324993A
IL324993A IL324993A IL32499325A IL324993A IL 324993 A IL324993 A IL 324993A IL 324993 A IL324993 A IL 324993A IL 32499325 A IL32499325 A IL 32499325A IL 324993 A IL324993 A IL 324993A
Authority
IL
Israel
Prior art keywords
treatment
bispecific antibody
subject
dose
dosing schedule
Prior art date
Application number
IL324993A
Other languages
English (en)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL324993A publication Critical patent/IL324993A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL324993A 2023-06-01 2024-05-31 שיטות לטיפול במיאלומה נפוצה IL324993A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363505640P 2023-06-01 2023-06-01
US202363588520P 2023-10-06 2023-10-06
US202363594771P 2023-10-31 2023-10-31
PCT/IB2024/055343 WO2024246856A1 (en) 2023-06-01 2024-05-31 Methods for treating multiple myeloma

Publications (1)

Publication Number Publication Date
IL324993A true IL324993A (he) 2026-01-01

Family

ID=91581060

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324993A IL324993A (he) 2023-06-01 2024-05-31 שיטות לטיפול במיאלומה נפוצה

Country Status (6)

Country Link
KR (1) KR20260020402A (he)
CN (1) CN121311245A (he)
AU (1) AU2024283100A1 (he)
IL (1) IL324993A (he)
MX (1) MX2025014342A (he)
WO (1) WO2024246856A1 (he)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
IL301361A (he) 2020-09-16 2023-05-01 Janssen Biotech Inc שיטות לטיפול במיאלומה נפוצה

Also Published As

Publication number Publication date
WO2024246856A1 (en) 2024-12-05
MX2025014342A (es) 2026-01-07
AU2024283100A1 (en) 2026-01-22
KR20260020402A (ko) 2026-02-11
CN121311245A (zh) 2026-01-09

Similar Documents

Publication Publication Date Title
US11952426B2 (en) Methods for treating multiple myeloma
US12098210B2 (en) Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies
JP2023542124A (ja) 多発性骨髄腫を治療するための方法
US20250064928A1 (en) Methods for treating multiple myeloma
WO2024095173A1 (en) Methods of treating cancers
IL323989A (he) שיטות לטיפול במיאלומה נפוצה
IL324993A (he) שיטות לטיפול במיאלומה נפוצה
CA3212336A1 (en) Methods for treating multiple myeloma
WO2025094085A1 (en) Combination regimens for treating multiple myeloma
WO2025096717A1 (en) Methods for treating multiple myeloma
US20230295292A1 (en) Methods of treating cancers and enhancing efficacy of gprc5dxcd3 bispecific antibodies
WO2025243241A1 (en) Methods for treating multiple myeloma
WO2025094107A1 (en) Methods for treating high-risk smoldering multiple myeloma
WO2025019733A2 (en) Methods for treating multiple myeloma
TW202608482A (zh) 用於治療多發性骨髓瘤之方法
EA050839B1 (ru) Способы лечения множественной миеломы